Clozapine and the risk of haematological malignancies – Authors' reply,The Lancet Psychiatry

当前位置： X-MOL 学术 › Lancet Psychiatry › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Clozapine and the risk of haematological malignancies – Authors' reply
The Lancet Psychiatry ( IF 64.3 ) Pub Date : 2022-06-16 , DOI: 10.1016/s2215-0366(22)00204-8
Jari Tiihonen ₁ , Antti Tanskanen ₂ , J Simon Bell ₃ , Jessica L Dawson ₄ , Vesa Kataja ₅ , Heidi Taipale ₆

Affiliation

Department of Forensic Psychiatry, Niuvanniemi Hospital, University of Eastern Finland, Kuopio, Finland; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm 11364, Sweden; Center for Psychiatry Research, Stockholm City Council, Stockholm, Sweden; Neuroscience Center, University of Helsinki, Helsinki, Finland.
Department of Forensic Psychiatry, Niuvanniemi Hospital, University of Eastern Finland, Kuopio, Finland; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm 11364, Sweden; Center for Psychiatry Research, Stockholm City Council, Stockholm, Sweden.
School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland; Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, VIC, Australia.
Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, VIC, Australia; SA Pharmacy, Flinders Medical Centre, Bedford Park, Adelaide, SA, Australia.
Kaiku Health, Helsinki, Finland.
Department of Forensic Psychiatry, Niuvanniemi Hospital, University of Eastern Finland, Kuopio, Finland; School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm 11364, Sweden; Center for Psychiatry Research, Stockholm City Council, Stockholm, Sweden.